GLENMARK:NSE:NSE-Glenmark Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1636.1

Change

0.00 (0.00)%

Market Cap

USD 447.54B

Volume

0.30M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-156.65 (-2.59%)

USD 1,561.24B
MANKIND:NSE Mankind Pharma Ltd

-53.00 (-1.80%)

USD 1,185.39B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-2.30 (-0.17%)

USD 1,157.53B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-39.90 (-1.17%)

USD 1,152.44B
LUPIN:NSE Lupin Limited

-8.55 (-0.36%)

USD 1,016.49B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-14.35 (-1.47%)

USD 978.76B
AUROPHARMA:NSE Aurobindo Pharma Limited

-6.65 (-0.50%)

USD 737.59B
ALKEM:NSE Alkem Laboratories Limited

+24.35 (+0.44%)

USD 665.89B
IPCALAB:NSE IPCA Laboratories Limited

-16.00 (-0.92%)

USD 421.90B
AJANTPHARM:NSE Ajanta Pharma Limited

+73.50 (+2.56%)

USD 380.23B

ETFs Containing GLENMARK:NSE

SCIF 0.00 % 0.83 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.34% 70% C- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.34% 70% C- 63% D
Trailing 12 Months  
Capital Gain 83.28% 90% A- 88% B+
Dividend Return 0.28% 25% F 22% F
Total Return 83.56% 90% A- 88% B+
Trailing 5 Years  
Capital Gain 376.72% 72% C 68% D+
Dividend Return 3.64% 34% F 26% F
Total Return 380.36% 72% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 38.69% 66% D+ 53% F
Dividend Return 39.21% 66% D+ 53% F
Total Return 0.52% 52% F 44% F
Risk Return Profile  
Volatility (Standard Deviation) 56.94% 39% F 42% F
Risk Adjusted Return 68.86% 73% C 50% F
Market Capitalization 447.54B 89% A- 90% A-

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.